N/A
N=52
Gait Re-education Program in Subjects With Parkinson´s Disease
Parkinson Disease
Bottom Line
View on ClinicalTrials.gov: NCT05131880 ↗Enrolled (actual)
52
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: Physical Performance: The Short Physical Performance Battery (SPPB) — 8.78; 9.60; 8.89; 10.72 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Gait Re-education Program Using the Fisior® Mat Sequential Training System in Subjects with Parkinson's Disease (Other)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- Universidad Europea de Madrid
- Primary completion
- Apr 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Physical Performance: The Short Physical Performance Battery (SPPB) |
8.78; 9.60; 8.89; 10.72 | — |
| PRIMARY Walk Speed: Timed Up and Go (TUG) Test |
0.55; 0.59; 0.53; 0.67 | — |
| PRIMARY Risk of Falls: FallSkip |
26.48; 25.4; 26.85; 21.40 | — |
| PRIMARY Functionality and Independence: Barthel Index |
87.59; 91.8 | — |
| SECONDARY General Satisfaction |
4.3; 4.5 | — |
Summary
Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called "TAPIZ FISIOR"- motor control and learning added to a conventional physiotherapy program; and the other group will perform only a conventional physiotherapy program. The evaluators will be unaware of the patient's treatment status.
Eligibility Criteria
Inclusion Criteria
- Older than 50 years.
- Diagnosed Parkinson Disease.
- Not to be institutionalized.
- Barthel index scores of ≥ 60.
- Ability to communicate and to get up and walk at least 10 m (33 ft)
Exclusion Criteria
- Medical criteria for contraindication of treatment.
- Severe behavioral problems that hinder participation in the training program.
Data sourced from ClinicalTrials.gov (NCT05131880). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.